Anika Therapeutics, Inc. Altman Z-Score
ANIK|Modified Z-Score (book value) based on FY2025 data
Anika Therapeutics, Inc.'s Altman Z-Score of 2.28 places the company in the "grey zone" (1.23–2.9). This range has historically shown mixed outcomes in the Altman model (FY2025).
Based on SEC 10-K filings.
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Grey Zone (1.23 - 2.9)
Grey zone - moderate risk, requires monitoring
The Altman Z-Score predicts bankruptcy risk using 5 financial ratios. Learn more
Components: book value of equity, working capital, retained earnings, EBIT, and revenue-to-assets — all derived from SEC FY2025 10-K filings.
5-Factor Decomposition
| Component | Ratio | Weight | Contribution |
|---|---|---|---|
| Working Capital / Total Assets | 0.428 | 0.717 | 0.307 |
| Retained Earnings / Total Assets | 0.319 | 0.847 | 0.271 |
| EBIT / Total Assets | -0.058 | 3.107 | -0.180 |
| Book Equity / Total Liabilities | 3.065 | 0.420 | 1.287 |
| Revenue / Total Assets | 0.593 | 0.998 | 0.592 |
| Total Z-Score | 2.28 | ||
As of FY2025 · SEC 10-K · Updated Jun 24, 2026
Z-Score Zones
Safe Zone - Company is in strong financial health with low bankruptcy risk.
Grey Zone - Uncertain financial position. Requires closer monitoring.
Distress Zone - Elevated probability of financial difficulties.